CP 466,722 is an inhibitor of ataxia-telangiectasia mutated (ATM) kinase that inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of the ATM targets SMC1, Chk2, and p53 in HeLa cells when used at a concentration of 10 μM. It is selective for ATM over PI3K and PIKK in HFF(hTERT) and A-T(hTERT) fibroblasts, respectively. CP 466,722 decreases cell survival in response to ionizing radiation in HeLa cells. It is also cytotoxic to MCF-7 and SKBr-3 breast cancer cells (IC50s = 16.92 and 12.78 μM, respectively).
CP466722 is a competetive, reversible inhbitor of Ataxia telangiectasia (A-T) mutated (ATM) kinase
ChEBI: 2-(6,7-dimethoxy-4-quinazolinyl)-5-(2-pyridinyl)-1,2,4-triazol-3-amine is a member of quinazolines.
[1]. guo, k., et al., development of a cell-based, high-throughput screening assay for atm kinase inhibitors. j biomol screen, 2014. 19(4): p. 538-46.
[2]. nadkarni, a., et al., atm inhibitor ku-55933 increases the tmz responsiveness of only inherently tmz sensitive gbm cells. j neurooncol, 2012. 110(3): p. 349-57.
[3]. rainey, m.d., et al., transient inhibition of atm kinase is sufficient to enhance cellular sensitivity to ionizing radiation. cancer res, 2008. 68(18): p. 7466-74.
